Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission

BACKGROUND The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. METHODS In total, 241 patients who were newly d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2014-07, Vol.120 (14), p.2122-2129
Hauptverfasser: Pingali, Sai Ravi, Jewell, Sarah W., Havlat, Luiza, Bast, Martin A., Thompson, Jonathan R., Eastwood, Daniel C., Bartlett, Nancy L., Armitage, James O., Wagner‐Johnston, Nina D., Vose, Julie M., Fenske, Timothy S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2129
container_issue 14
container_start_page 2122
container_title Cancer
container_volume 120
creator Pingali, Sai Ravi
Jewell, Sarah W.
Havlat, Luiza
Bast, Martin A.
Thompson, Jonathan R.
Eastwood, Daniel C.
Bartlett, Nancy L.
Armitage, James O.
Wagner‐Johnston, Nina D.
Vose, Julie M.
Fenske, Timothy S.
description BACKGROUND The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. METHODS In total, 241 patients who were newly diagnosed with cHL between January 2000 and December 2010 at 3 participating tertiary care centers and achieved complete remission after first‐line therapy were retrospectively analyzed. Of these, there were 174 patients in the routine surveillance imaging group and 67 patients in the clinical surveillance group, based on the intended mode of surveillance. In the routine surveillance imaging group, the intended plan of surveillance included computed tomography and/or positron emission tomography scans; whereas, in the clinical surveillance group, the intended plan of surveillance was clinical examination and laboratory studies, and scans were obtained only to evaluate concerning signs or symptoms. Baseline patient characteristics, prognostic features, treatment records, and outcomes were collected. The primary objective was to compare overall survival for patients in both groups. For secondary objectives, we compared the success of second‐line therapy and estimated the costs of imaging for each group. RESULTS After 5 years of follow‐up, the overall survival rate was 97% (95% confidence interval, 92%‐99%) in the routine surveillance imaging group and 96% (95% confidence interval, 87%‐99%) in the clinical surveillance group (P = .41). There were few relapses in each group, and all patients who relapsed in both groups achieved complete remission with second‐line therapy. The charges associated with routine surveillance imaging were significantly higher than those for the clinical surveillance strategy, with no apparent clinical benefit. CONCLUSIONS Clinical surveillance was not inferior to routine surveillance imaging in patients with cHL who achieved complete remission with frontline therapy. Routine surveillance imaging was associated with significantly increased estimated imaging charges. Cancer 2014;120:2122–2129. © 2014 American Cancer Society. Clinical surveillance is not inferior to routine surveillance imaging for patients with classical Hodgkin lymphoma who achieve complete remission with frontline therapy. Routine surveillance imaging is associated with significantly increased estimated imaging charges.
doi_str_mv 10.1002/cncr.28698
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1542649615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1542649615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4298-af4a5cd134bdbea5f8b909c4d191cc096cfdb7198c80eebd34edb03c6195a1433</originalsourceid><addsrcrecordid>eNp9kEtLxDAQgIMouq5e_AGSiyBC16RNu81RFl-wKIiCt5ImkzWaNjVplf33Zt1Vb54yM3yZx4fQESUTSkh6LlvpJ2lZ8HILjSjh04RQlm6jESGkTHKWPe-h_RBeYzpN82wX7aVsSmkMRyjMTWN6UHjojTX9EjuNvYtJCzgM_gOMtaKVgE0jFqZdYO08llaEYKSw-MapxZtpsV023YtrBO5Eb6DtA45FbXzosXRNZ6EH7KEx8ZtrD9COFjbA4eYdo6ery8fZTTK_v76dXcwTyVJeJkIzkUtFM1arGkSuy5oTLpminEpJeCG1qqeUl7IkALXKGKiaZLKgPBeUZdkYna77dt69DxD6Ki4gYXUQuCFUNGdpwXhB84ierVHpXQgedNX5eLFfVpRUK8nVSnL1LTnCx5u-Q92A-kV_rEbgZAOIEC1pHw2a8MeVBSni_pGja-7TWFj-M7Ka3c0e1sO_AAl1l64</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1542649615</pqid></control><display><type>article</type><title>Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Pingali, Sai Ravi ; Jewell, Sarah W. ; Havlat, Luiza ; Bast, Martin A. ; Thompson, Jonathan R. ; Eastwood, Daniel C. ; Bartlett, Nancy L. ; Armitage, James O. ; Wagner‐Johnston, Nina D. ; Vose, Julie M. ; Fenske, Timothy S.</creator><creatorcontrib>Pingali, Sai Ravi ; Jewell, Sarah W. ; Havlat, Luiza ; Bast, Martin A. ; Thompson, Jonathan R. ; Eastwood, Daniel C. ; Bartlett, Nancy L. ; Armitage, James O. ; Wagner‐Johnston, Nina D. ; Vose, Julie M. ; Fenske, Timothy S.</creatorcontrib><description>BACKGROUND The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. METHODS In total, 241 patients who were newly diagnosed with cHL between January 2000 and December 2010 at 3 participating tertiary care centers and achieved complete remission after first‐line therapy were retrospectively analyzed. Of these, there were 174 patients in the routine surveillance imaging group and 67 patients in the clinical surveillance group, based on the intended mode of surveillance. In the routine surveillance imaging group, the intended plan of surveillance included computed tomography and/or positron emission tomography scans; whereas, in the clinical surveillance group, the intended plan of surveillance was clinical examination and laboratory studies, and scans were obtained only to evaluate concerning signs or symptoms. Baseline patient characteristics, prognostic features, treatment records, and outcomes were collected. The primary objective was to compare overall survival for patients in both groups. For secondary objectives, we compared the success of second‐line therapy and estimated the costs of imaging for each group. RESULTS After 5 years of follow‐up, the overall survival rate was 97% (95% confidence interval, 92%‐99%) in the routine surveillance imaging group and 96% (95% confidence interval, 87%‐99%) in the clinical surveillance group (P = .41). There were few relapses in each group, and all patients who relapsed in both groups achieved complete remission with second‐line therapy. The charges associated with routine surveillance imaging were significantly higher than those for the clinical surveillance strategy, with no apparent clinical benefit. CONCLUSIONS Clinical surveillance was not inferior to routine surveillance imaging in patients with cHL who achieved complete remission with frontline therapy. Routine surveillance imaging was associated with significantly increased estimated imaging charges. Cancer 2014;120:2122–2129. © 2014 American Cancer Society. Clinical surveillance is not inferior to routine surveillance imaging for patients with classical Hodgkin lymphoma who achieve complete remission with frontline therapy. Routine surveillance imaging is associated with significantly increased estimated imaging charges.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.28698</identifier><identifier>PMID: 24711253</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley-Blackwell</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bleomycin - administration &amp; dosage ; Cause of Death ; Dacarbazine - administration &amp; dosage ; Direct Service Costs ; Doxorubicin - administration &amp; dosage ; Female ; first complete remission ; Follow-Up Studies ; Hematologic and hematopoietic diseases ; Hodgkin Disease - diagnostic imaging ; Hodgkin Disease - economics ; Hodgkin Disease - pathology ; Hodgkin Disease - therapy ; Hodgkin lymphoma ; Humans ; Induction Chemotherapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Limited utility ; Male ; Medical sciences ; Middle Aged ; Population Surveillance - methods ; Positron-Emission Tomography - economics ; Positron-Emission Tomography - utilization ; Recurrence ; routine surveillance imaging ; Tomography, X-Ray Computed - economics ; Tomography, X-Ray Computed - utilization ; Tumors ; United States ; Vinblastine - administration &amp; dosage</subject><ispartof>Cancer, 2014-07, Vol.120 (14), p.2122-2129</ispartof><rights>2014 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>2014 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4298-af4a5cd134bdbea5f8b909c4d191cc096cfdb7198c80eebd34edb03c6195a1433</citedby><cites>FETCH-LOGICAL-c4298-af4a5cd134bdbea5f8b909c4d191cc096cfdb7198c80eebd34edb03c6195a1433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.28698$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.28698$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46387,46811</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28606096$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24711253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pingali, Sai Ravi</creatorcontrib><creatorcontrib>Jewell, Sarah W.</creatorcontrib><creatorcontrib>Havlat, Luiza</creatorcontrib><creatorcontrib>Bast, Martin A.</creatorcontrib><creatorcontrib>Thompson, Jonathan R.</creatorcontrib><creatorcontrib>Eastwood, Daniel C.</creatorcontrib><creatorcontrib>Bartlett, Nancy L.</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Wagner‐Johnston, Nina D.</creatorcontrib><creatorcontrib>Vose, Julie M.</creatorcontrib><creatorcontrib>Fenske, Timothy S.</creatorcontrib><title>Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. METHODS In total, 241 patients who were newly diagnosed with cHL between January 2000 and December 2010 at 3 participating tertiary care centers and achieved complete remission after first‐line therapy were retrospectively analyzed. Of these, there were 174 patients in the routine surveillance imaging group and 67 patients in the clinical surveillance group, based on the intended mode of surveillance. In the routine surveillance imaging group, the intended plan of surveillance included computed tomography and/or positron emission tomography scans; whereas, in the clinical surveillance group, the intended plan of surveillance was clinical examination and laboratory studies, and scans were obtained only to evaluate concerning signs or symptoms. Baseline patient characteristics, prognostic features, treatment records, and outcomes were collected. The primary objective was to compare overall survival for patients in both groups. For secondary objectives, we compared the success of second‐line therapy and estimated the costs of imaging for each group. RESULTS After 5 years of follow‐up, the overall survival rate was 97% (95% confidence interval, 92%‐99%) in the routine surveillance imaging group and 96% (95% confidence interval, 87%‐99%) in the clinical surveillance group (P = .41). There were few relapses in each group, and all patients who relapsed in both groups achieved complete remission with second‐line therapy. The charges associated with routine surveillance imaging were significantly higher than those for the clinical surveillance strategy, with no apparent clinical benefit. CONCLUSIONS Clinical surveillance was not inferior to routine surveillance imaging in patients with cHL who achieved complete remission with frontline therapy. Routine surveillance imaging was associated with significantly increased estimated imaging charges. Cancer 2014;120:2122–2129. © 2014 American Cancer Society. Clinical surveillance is not inferior to routine surveillance imaging for patients with classical Hodgkin lymphoma who achieve complete remission with frontline therapy. Routine surveillance imaging is associated with significantly increased estimated imaging charges.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bleomycin - administration &amp; dosage</subject><subject>Cause of Death</subject><subject>Dacarbazine - administration &amp; dosage</subject><subject>Direct Service Costs</subject><subject>Doxorubicin - administration &amp; dosage</subject><subject>Female</subject><subject>first complete remission</subject><subject>Follow-Up Studies</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hodgkin Disease - diagnostic imaging</subject><subject>Hodgkin Disease - economics</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin Disease - therapy</subject><subject>Hodgkin lymphoma</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Limited utility</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Population Surveillance - methods</subject><subject>Positron-Emission Tomography - economics</subject><subject>Positron-Emission Tomography - utilization</subject><subject>Recurrence</subject><subject>routine surveillance imaging</subject><subject>Tomography, X-Ray Computed - economics</subject><subject>Tomography, X-Ray Computed - utilization</subject><subject>Tumors</subject><subject>United States</subject><subject>Vinblastine - administration &amp; dosage</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAQgIMouq5e_AGSiyBC16RNu81RFl-wKIiCt5ImkzWaNjVplf33Zt1Vb54yM3yZx4fQESUTSkh6LlvpJ2lZ8HILjSjh04RQlm6jESGkTHKWPe-h_RBeYzpN82wX7aVsSmkMRyjMTWN6UHjojTX9EjuNvYtJCzgM_gOMtaKVgE0jFqZdYO08llaEYKSw-MapxZtpsV023YtrBO5Eb6DtA45FbXzosXRNZ6EH7KEx8ZtrD9COFjbA4eYdo6ery8fZTTK_v76dXcwTyVJeJkIzkUtFM1arGkSuy5oTLpminEpJeCG1qqeUl7IkALXKGKiaZLKgPBeUZdkYna77dt69DxD6Ki4gYXUQuCFUNGdpwXhB84ierVHpXQgedNX5eLFfVpRUK8nVSnL1LTnCx5u-Q92A-kV_rEbgZAOIEC1pHw2a8MeVBSni_pGja-7TWFj-M7Ka3c0e1sO_AAl1l64</recordid><startdate>20140715</startdate><enddate>20140715</enddate><creator>Pingali, Sai Ravi</creator><creator>Jewell, Sarah W.</creator><creator>Havlat, Luiza</creator><creator>Bast, Martin A.</creator><creator>Thompson, Jonathan R.</creator><creator>Eastwood, Daniel C.</creator><creator>Bartlett, Nancy L.</creator><creator>Armitage, James O.</creator><creator>Wagner‐Johnston, Nina D.</creator><creator>Vose, Julie M.</creator><creator>Fenske, Timothy S.</creator><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140715</creationdate><title>Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission</title><author>Pingali, Sai Ravi ; Jewell, Sarah W. ; Havlat, Luiza ; Bast, Martin A. ; Thompson, Jonathan R. ; Eastwood, Daniel C. ; Bartlett, Nancy L. ; Armitage, James O. ; Wagner‐Johnston, Nina D. ; Vose, Julie M. ; Fenske, Timothy S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4298-af4a5cd134bdbea5f8b909c4d191cc096cfdb7198c80eebd34edb03c6195a1433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bleomycin - administration &amp; dosage</topic><topic>Cause of Death</topic><topic>Dacarbazine - administration &amp; dosage</topic><topic>Direct Service Costs</topic><topic>Doxorubicin - administration &amp; dosage</topic><topic>Female</topic><topic>first complete remission</topic><topic>Follow-Up Studies</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hodgkin Disease - diagnostic imaging</topic><topic>Hodgkin Disease - economics</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin Disease - therapy</topic><topic>Hodgkin lymphoma</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Limited utility</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Population Surveillance - methods</topic><topic>Positron-Emission Tomography - economics</topic><topic>Positron-Emission Tomography - utilization</topic><topic>Recurrence</topic><topic>routine surveillance imaging</topic><topic>Tomography, X-Ray Computed - economics</topic><topic>Tomography, X-Ray Computed - utilization</topic><topic>Tumors</topic><topic>United States</topic><topic>Vinblastine - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pingali, Sai Ravi</creatorcontrib><creatorcontrib>Jewell, Sarah W.</creatorcontrib><creatorcontrib>Havlat, Luiza</creatorcontrib><creatorcontrib>Bast, Martin A.</creatorcontrib><creatorcontrib>Thompson, Jonathan R.</creatorcontrib><creatorcontrib>Eastwood, Daniel C.</creatorcontrib><creatorcontrib>Bartlett, Nancy L.</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Wagner‐Johnston, Nina D.</creatorcontrib><creatorcontrib>Vose, Julie M.</creatorcontrib><creatorcontrib>Fenske, Timothy S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pingali, Sai Ravi</au><au>Jewell, Sarah W.</au><au>Havlat, Luiza</au><au>Bast, Martin A.</au><au>Thompson, Jonathan R.</au><au>Eastwood, Daniel C.</au><au>Bartlett, Nancy L.</au><au>Armitage, James O.</au><au>Wagner‐Johnston, Nina D.</au><au>Vose, Julie M.</au><au>Fenske, Timothy S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2014-07-15</date><risdate>2014</risdate><volume>120</volume><issue>14</issue><spage>2122</spage><epage>2129</epage><pages>2122-2129</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. METHODS In total, 241 patients who were newly diagnosed with cHL between January 2000 and December 2010 at 3 participating tertiary care centers and achieved complete remission after first‐line therapy were retrospectively analyzed. Of these, there were 174 patients in the routine surveillance imaging group and 67 patients in the clinical surveillance group, based on the intended mode of surveillance. In the routine surveillance imaging group, the intended plan of surveillance included computed tomography and/or positron emission tomography scans; whereas, in the clinical surveillance group, the intended plan of surveillance was clinical examination and laboratory studies, and scans were obtained only to evaluate concerning signs or symptoms. Baseline patient characteristics, prognostic features, treatment records, and outcomes were collected. The primary objective was to compare overall survival for patients in both groups. For secondary objectives, we compared the success of second‐line therapy and estimated the costs of imaging for each group. RESULTS After 5 years of follow‐up, the overall survival rate was 97% (95% confidence interval, 92%‐99%) in the routine surveillance imaging group and 96% (95% confidence interval, 87%‐99%) in the clinical surveillance group (P = .41). There were few relapses in each group, and all patients who relapsed in both groups achieved complete remission with second‐line therapy. The charges associated with routine surveillance imaging were significantly higher than those for the clinical surveillance strategy, with no apparent clinical benefit. CONCLUSIONS Clinical surveillance was not inferior to routine surveillance imaging in patients with cHL who achieved complete remission with frontline therapy. Routine surveillance imaging was associated with significantly increased estimated imaging charges. Cancer 2014;120:2122–2129. © 2014 American Cancer Society. Clinical surveillance is not inferior to routine surveillance imaging for patients with classical Hodgkin lymphoma who achieve complete remission with frontline therapy. Routine surveillance imaging is associated with significantly increased estimated imaging charges.</abstract><cop>Hoboken, NJ</cop><pub>Wiley-Blackwell</pub><pmid>24711253</pmid><doi>10.1002/cncr.28698</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2014-07, Vol.120 (14), p.2122-2129
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_1542649615
source Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bleomycin - administration & dosage
Cause of Death
Dacarbazine - administration & dosage
Direct Service Costs
Doxorubicin - administration & dosage
Female
first complete remission
Follow-Up Studies
Hematologic and hematopoietic diseases
Hodgkin Disease - diagnostic imaging
Hodgkin Disease - economics
Hodgkin Disease - pathology
Hodgkin Disease - therapy
Hodgkin lymphoma
Humans
Induction Chemotherapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Limited utility
Male
Medical sciences
Middle Aged
Population Surveillance - methods
Positron-Emission Tomography - economics
Positron-Emission Tomography - utilization
Recurrence
routine surveillance imaging
Tomography, X-Ray Computed - economics
Tomography, X-Ray Computed - utilization
Tumors
United States
Vinblastine - administration & dosage
title Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A57%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limited%20utility%20of%20routine%20surveillance%20imaging%20for%20classical%20Hodgkin%20lymphoma%20patients%20in%20first%20complete%20remission&rft.jtitle=Cancer&rft.au=Pingali,%20Sai%20Ravi&rft.date=2014-07-15&rft.volume=120&rft.issue=14&rft.spage=2122&rft.epage=2129&rft.pages=2122-2129&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.28698&rft_dat=%3Cproquest_cross%3E1542649615%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1542649615&rft_id=info:pmid/24711253&rfr_iscdi=true